Navigation Links
Sinovac Reports Unaudited Second Quarter Financial Results
Date:8/14/2014

s_span">-

-

-

-Total sales12,090

100.0%

17,452

100.0%Cost of goods sold3,025

25.0%

3,861

22.1%Gross profit9,065

75.0%

13,591

77.9%In the second quarter 2014, total sales were $12.1 million, a decrease of 30.7% from $17.5 million during the same period in 2013. This decrease was primarily due to softer demand in the private vaccine market. China's CDCs have been also more conservative in their vaccination programs. Nevertheless, the Company achieved record sales in the second quarter of 2013, which resulted in a higher basis for year-over-year comparison.

Gross profit was $9.1 million in the second quarter 2014, compared to $13.6 million in the prior year period. Gross margin decreased to 75.0% from 77.9% in the prior year period. The slight decrease in gross margin is attributable to idle capacity in the Company's influenza facility during the second quarter, which was charged to cost of goods sold.

Selling, general and administrative expenses for the second quarter 2014 were $8.6 million, compared to $8.8 million in the same period of 2013.

R&D expenses for the second quarter of 2014 were $3.3 million, a $1.2 million increase over the same period in 2013. These expenses are primarily related to the continued advancement of pipeline vaccine candidates, including sIPV, EV71, PPV, and varicella vaccine.

Net loss attributable to common st
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results
2. Sinovac to Participate in UBS Asia Healthcare CEO Summit in November 2013
3. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
5. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
6. Pressure BioSciences, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update
7. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
8. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
9. MarketResearch.com: New Biotechnology Market Research Reports Added to Kalorama Information Knowledge Center
10. GenVec Reports Second Quarter 2014 Financial Results
11. BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  CytomX, a biotechnology ... cancer, today announced the appointments of Bob ... Cynthia Ladd as senior vice president and ... chief financial officer of Onyx Pharmaceuticals, an Amgen ... consultant and legal counsel to several leading biotech ...
(Date:5/27/2015)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ), ... innovative therapies primarily in the areas of dermatology ... of the Company,s Series A and Series A-1 ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March 31, ... Series A Preferred Stock and Series A-1 Preferred ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 WORMS, ... Grace & Co. (NYSE: GRA) announces that its ... manufacturing practice (GMP) certification from EXCiPACTâ„¢, an independent ... pharmaceutical excipients. , All three Grace ... pharmaceutical grade excipient silica gels have now received ...
(Date:5/26/2015)... , May 26, 2015   Intrexon Corporation (NYSE: ... that Gregory Frost , Ph.D., Senior Vice President and ... 2015 Global Healthcare Conference on Wednesday, June 3 rd , ... New York City . About ... is Powering the Bioindustrial Revolution with Better DNA ™ ...
Breaking Biology Technology:CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2
... Business Development Efforts, SALT LAKE CITY, Sept. ... the development of molecular diagnostic and motion preserving,technologies ... Joe Ross has,joined the executive management team as ... In this new role, Ross will oversee Axial ...
... 14% from the, prior year,s third quarter - Earnings per share ... - Operating cash flow of $23 million, (Year-to-date operating cash flow of ... ... Martek Biosciences,Corporation (Nasdaq: MATK ) today announced its financial results ...
... and National Development in Taiwan, 1950-2000, Celebrates ... Editor of a Comprehensive History of ... Dialogue on a National Health Care System ... Worth Studying, NEW YORK, Sept. 4 ...
Cached Biology Technology:Axial Biotech appoints new Vice President of Strategic Initiatives 2Martek Announces Third Quarter 2008 Financial Results 2Martek Announces Third Quarter 2008 Financial Results 3Martek Announces Third Quarter 2008 Financial Results 4Martek Announces Third Quarter 2008 Financial Results 5Martek Announces Third Quarter 2008 Financial Results 6Martek Announces Third Quarter 2008 Financial Results 7Martek Announces Third Quarter 2008 Financial Results 8Martek Announces Third Quarter 2008 Financial Results 9Martek Announces Third Quarter 2008 Financial Results 10ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan 2ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan 3
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/20/2015)... May 20, 2015 NXT-ID, Inc. (NASDAQ: ... wholly owned subsidiary, 3D-ID LLC, a company engaged in ... for the biometrics technology portion of the recently awarded ... the Department of the Army. 3D-ID LLC ... for government, law enforcement and security agencies. ...
(Date:5/19/2015)...  Technology is rapidly advancing, outpacing enterprises, ability to ... Passwords and their management are soon to be rendered ... such as those developed by the FIDO Alliance™. With ... for BYOD, COPE, IoT, and mobile payments, the interconnected ... In response to the call for seamless, ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
... pollution and heavy fishingare adding insult to injury in ... by the Wildlife Conservation Society and the University of ... found that pollution and overfishing on reef systems have ... wormsthat further degrade corals, a discovery that underlines the ...
... at UCLA,s Jonsson Cancer Center found that the children ... having retinoblastoma, a malignant tumor of the retina which ... which focused on babies born in California, also found ... for retinoblastoma, as were children born to women with ...
... are overweight or obese can encounter a host of health ... children grow and develop, at least initially. In a ... a team led by a University of Iowa researcher compared ... obese mothers with those born to normal-weight mothers. ...
Cached Biology News:Microbes, sponges, and worms add to coral reef woes 2Microbes, sponges, and worms add to coral reef woes 3US-born Latinas at great risk of having babies with retinoblastoma 2Infants of overweight mothers grow more slowly 2Infants of overweight mothers grow more slowly 3
Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...
... recombinant IFNA2. Immunogen: Human IFNA2 ... in E. coli. The biological activity was ... OMIM: 147562, GeneID: ... MA Code: ABV0P9DPB ...
... longer need to perform time consuming and inaccurate ... Surveyor, any found variants of the sample when ... in our mutation electropherogram as a sharp peak. ... analysis mode is over 99%, with sensitivity to ...
...
Biology Products: